Sotera Health’s second quarter was marked by broad-based growth across its business units, which drove a positive market reaction. Management credited robust demand in both core sterilization (Sterigenics) and isotope supply (Nordion), coupled with improved customer engagement at Nelson Labs, for the outperformance. CEO Alton Shader highlighted that "Sterigenics built on strong momentum from Q1, delivering 7% constant currency revenue growth," while Nordion benefited from favorable Cobalt-60 shipment timing. The company also benefited from higher pricing and operational efficiencies, with Shader emphasizing the importance of customer relationships and technical expertise in differentiating Sotera Health’s offerings.
Is now the time to buy SHC? Find out in our full research report (it’s free for active Edge members).
Sotera Health Company (SHC) Q2 CY2026 Highlights:
- Revenue: $321.4 million vs analyst estimates of $309.6 million (9.2% year-on-year growth, 3.8% beat)
- Adjusted EPS: $0.26 vs analyst estimates of $0.24 (8.7% beat)
- Adjusted EBITDA: $165.7 million vs analyst estimates of $157.7 million (51.6% margin, 5.1% beat)
- The company slightly lifted its revenue guidance for the full year to $1.25 billion at the midpoint from $1.24 billion
- Management raised its full-year Adjusted EPS guidance to $0.98 at the midpoint, a 1% increase
- Operating Margin: 33.2%, up from 30% in the same quarter last year
- Organic Revenue rose 8% year on year (beat)
- Market Capitalization: $5.39 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Sotera Health Company’s Q2 Earnings Call
- Chris Charlton (BMO): asked about the drivers behind Nelson Labs’ strong quarter and visibility into the second half. CEO Alton Shader cited new customer wins and ongoing demand, expressing confidence in sustained performance.
- Elizabeth Koslosky (Goldman Sachs): inquired about Shader’s top priorities as new CEO and opportunities for business synergies. Shader emphasized talent assessment, customer partnership, and potential for greater cross-business collaboration.
- Luke Sergott (Barclays): questioned differentiation in Sterigenics’ growth and technology mix, including potential impacts from regulatory headwinds. Shader highlighted a higher U.S. and EO exposure, with no slowdown in demand or significant regulatory effect seen.
- Casey Woodring (JPMorgan): asked what gave management confidence to raise the high end of guidance. Shader pointed to visibility from new capacity, customer onboarding, and backlog analysis as key factors.
- Michael Polark (Wolfe Research): requested a litigation update and details on a large customer outsourcing sterilization. Executive Chairman Michael Petras explained legal milestones, and CFO Jonathan Lyons confirmed the customer is shifting capacity to Sotera Health, supporting second-half growth.
Catalysts in Upcoming Quarters
Looking forward, the StockStory team will be closely monitoring (1) the ramp-up of new X-ray sterilization capacity and associated revenue contribution, (2) the onboarding progress of the large customer outsourcing sterilization services, and (3) continued execution on cross-segment commercial strategies, especially between Sterigenics and Nelson Labs. Developments in ongoing litigation and updates on capital deployment priorities will also be important to track.
Sotera Health Company currently trades at $18.89, up from $17.98 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
